Study Condition(s): Psoriasis

A Study of Mirikizumab in Participants With Plaque Psoriasis

Study Alias: AMBP

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT03718884 {{ currentLocaleObject.registryAnchorText }}

Recruiting Recruiting

Study Purpose

This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab.

  The study will last about 23 weeks for each participant. Screening must be completed within 4
  weeks prior to study start.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

The study will last about 23 weeks for each participant, which includes 10 outpatient visits and 2 inpatient visits (with 3 overnights per visit).
  • Participants must have chronic plaque psoriasis for at least 6 months and are candidates for treatment with a prescription drug or light therapy
  • Participants must have moderate to severe plaque psoriasis, as determined by the investigator
  • Participants must not be pregnant or nursing (breastfeeding)
  • Participants must not have a history of an ongoing, chronic or recurrent infection, or evidence of tuberculosis
  • Participants must not have had major surgery within 8 weeks prior to first admission to the clinical site or during the study
  • Participants must not have a history of lymphoma (cancer of the lymph nodes), leukemia (blood cancer), or any other cancer
  • Participants must not require treatment with any drug given during the study. These include midazolam (sedative), warfarin (blood thinner), dextromethorphan (cough suppressant), omeprazole (stomach acid reducer) and caffeine
  • Participants must not have participated in any other research study with the study drug known as mirikizumab

Where to Participate

3 locations are currently available of 3 planned
Invalid Postal Code.
Please re-enter postal code.
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}
Alert Me Icon Sign up for email alerts about new Lilly trials and locations.

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.